Kurma Partners and Sunstone Life Science Ventures have led a CHF 20m series-A funding round for Switzerland-based Synendos Therapeutics, a company that develops therapies for central nervous system (CNS) disorders.
Fund invests in renewable chemistry, regenerative medicine and agri-food across the Netherlands, Belgium and parts of Germany
Company will operate with the GP's existing test and measurement companies in the US and Denmark
Numerous Italian GPs with a generalist approach have reshaped their activity towards the tech sector
GP plans to merge Atlantic with portfolio company Maced, in which it acquired a majority stake last year